Status:
COMPLETED
NMDA Modulation in Major Depressive Disorder in Late- Life
Lead Sponsor:
Chang Gung Memorial Hospital
Conditions:
Depressive Disorder, Major
Eligibility:
All Genders
55+ years
Phase:
PHASE2
Brief Summary
Major depressive disorder (MDD) is a complex and multi-factorial disorder. Most of the current antidepressants are based upon the monoamine hypothesis which cannot fully explain the etiology of depres...
Eligibility Criteria
Inclusion
- Have a DSM-IV (American Psychiatric Association 1994) diagnosis of MDD
- 17-item Hamilton Rating Scale for Depression total score ≥ 18
- Free of psychotropic drugs for at least 2 weeks
- Have a Mini-Mental State Examination (Folstein, Folstein et al. 1975) score ≥ 20
Exclusion
- Current substance abuse or history of substance dependence in the past 6 months
- Use of depot antipsychotics in the past 6 months
- History of epilepsy, head trauma, stroke or other serious medical or neurological illness
- Bipolar depression, schizophrenia or other psychotic disorder
- Moderate-severe suicidal risks
- Severe cognitive impairment
- Initiating or stopping formal psychotherapy within six weeks prior to enrollment
- A history of poor response to SSRIs or other antidepressants
- A history of previously received electroconvulsive therapy
- A history of severe adverse reaction to SSRIs or other antidepressants
- Inability to follow protocol
Key Trial Info
Start Date :
January 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2020
Estimated Enrollment :
136 Patients enrolled
Trial Details
Trial ID
NCT03414931
Start Date
January 1 2016
End Date
November 1 2020
Last Update
December 1 2020
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Chang Gung Memorial Hospital
Kaohsiung City, Taiwan, 886
2
China Medical University Hospital
Taichung, Taiwan, 404